| Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases FP Pons-Faudoa, A Ballerini, J Sakamoto, A Grattoni Biomedical microdevices 21 (2), 47, 2019 | 126 | 2019 |
| Preventive Efficacy of a Tenofovir Alafenamide Fumarate Nanofluidic Implant in SHIV‐Challenged Nonhuman Primates FP Pons‐Faudoa, A Sizovs, KA Shelton, Z Momin, JA Niles, LR Bushman, ... Advanced therapeutics 4 (3), 2000163, 2021 | 45 | 2021 |
| 2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis FP Pons-Faudoa, A Sizovs, N Di Trani, J Paez-Mayorga, G Bruno, ... Journal of Controlled Release 306, 89-96, 2019 | 45 | 2019 |
| Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting JW Romano, MM Baum, ZR Demkovich, F Diana, C Dobard, PL Feldman, ... AIDS research and human retroviruses 37 (6), 409-420, 2021 | 40 | 2021 |
| Nanofluidic microsystem for sustained intraocular delivery of therapeutics N Di Trani, P Jain, CYX Chua, JS Ho, G Bruno, A Susnjar, ... Nanomedicine: Nanotechnology, Biology and Medicine 16, 1-9, 2019 | 31 | 2019 |
| Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant FP Pons-Faudoa, ND Trani, A Sizovs, KA Shelton, Z Momin, LR Bushman, ... Pharmaceutics 12 (10), 981, 2020 | 13 | 2020 |
| Effect of ultra-violet exposure on production of mycosporine-like amino acids and lipids by Lyngbya purpurem R Chandra, FP Pons-Faudoa, RP Saldívar, BE Rittmann Biomass and Bioenergy 134, 105475, 2020 | 12 | 2020 |
| Extending drug release from implants via transcutaneous refilling with solid therapeutics N Di Trani, FP Pons‐Faudoa, A Sizovs, KA Shelton, MA Marzinke, ... Advanced Therapeutics 5 (2), 2100214, 2022 | 10 | 2022 |
| Implantable niche with local immunosuppression for islet allotransplantation achieves type 1 diabetes reversal in rats J Paez-Mayorga, JN Campa-Carranza, S Capuani, N Hernandez, HC Liu, ... Nature communications 13 (1), 7951, 2022 | 9 | 2022 |
| Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications A Sizovs, FP Pons-Faudoa, G Malgir, KA Shelton, LR Bushman, ... International Journal of Pharmaceutics 587, 119623, 2020 | 9 | 2020 |
| Long-acting refillable nanofluidic implant confers protection against SHIV infection in nonhuman primates FP Pons-Faudoa, N Di Trani, S Capuani, JN Campa-Carranza, B Nehete, ... Science Translational Medicine 15 (702), eadg2887, 2023 | 3* | 2023 |
| Preventive Efficacy of a Tenofovir Alafenamide Fumarate Nanofluidic Implant in SHIV‐Challenged Nonhuman Primates (Adv. Therap. 3/2021) FP Pons‐Faudoa, A Sizovs, KA Shelton, Z Momin, JA Niles, LR Bushman, ... Advanced Therapeutics 4 (3), 2170005, 2021 | 2 | 2021 |
| Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates FP Pons-Faudoa, N Di Trani, S Capuani, N Hernandez, AM Wood, ... Journal of Controlled Release 358, 116-127, 2023 | | 2023 |
| Implantable niche with local immunosuppression for islet allotransplantation achieves type 1 diabetes reversal in rats. J Paez-Mayorga, JN Campa-Carranza, S Capuani, N Hernandez, HC Liu, ... Nature Communications 13 (1), 7951-7951, 2022 | | 2022 |
| Sustained release of antiretroviral therapy from nanochannel delivery implant for HIV pre-exposure prophylaxis and treatment FP Pons Faudoa Instituto Tecnológico y de Estudios Superiores de Monterrey, 2021 | | 2021 |
Alessandro GrattoniChairman and Professor, Department of Nanomedicine, Houston Methodist Research InstituteVerified email at houstonmethodist.org
